S&P 500   3,976.40 (+0.33%)
DOW   33,840.90 (+0.18%)
QQQ   284.71 (+0.30%)
AAPL   144.39 (+1.22%)
MSFT   246.91 (-0.20%)
META   116.58 (+1.08%)
GOOGL   93.83 (+0.13%)
AMZN   89.62 (-0.81%)
TSLA   180.60 (+4.13%)
NVDA   174.79 (+1.81%)
NIO   12.98 (-3.21%)
BABA   92.89 (-1.36%)
AMD   70.39 (-0.11%)
T   19.33 (+1.10%)
MU   55.49 (+0.53%)
CGC   3.03 (-1.94%)
F   13.32 (+1.52%)
GE   82.36 (-1.52%)
DIS   94.71 (+2.33%)
AMC   6.00 (-1.15%)
PYPL   74.29 (+0.09%)
PFE   51.89 (+0.21%)
NFLX   327.58 (+5.58%)
S&P 500   3,976.40 (+0.33%)
DOW   33,840.90 (+0.18%)
QQQ   284.71 (+0.30%)
AAPL   144.39 (+1.22%)
MSFT   246.91 (-0.20%)
META   116.58 (+1.08%)
GOOGL   93.83 (+0.13%)
AMZN   89.62 (-0.81%)
TSLA   180.60 (+4.13%)
NVDA   174.79 (+1.81%)
NIO   12.98 (-3.21%)
BABA   92.89 (-1.36%)
AMD   70.39 (-0.11%)
T   19.33 (+1.10%)
MU   55.49 (+0.53%)
CGC   3.03 (-1.94%)
F   13.32 (+1.52%)
GE   82.36 (-1.52%)
DIS   94.71 (+2.33%)
AMC   6.00 (-1.15%)
PYPL   74.29 (+0.09%)
PFE   51.89 (+0.21%)
NFLX   327.58 (+5.58%)
S&P 500   3,976.40 (+0.33%)
DOW   33,840.90 (+0.18%)
QQQ   284.71 (+0.30%)
AAPL   144.39 (+1.22%)
MSFT   246.91 (-0.20%)
META   116.58 (+1.08%)
GOOGL   93.83 (+0.13%)
AMZN   89.62 (-0.81%)
TSLA   180.60 (+4.13%)
NVDA   174.79 (+1.81%)
NIO   12.98 (-3.21%)
BABA   92.89 (-1.36%)
AMD   70.39 (-0.11%)
T   19.33 (+1.10%)
MU   55.49 (+0.53%)
CGC   3.03 (-1.94%)
F   13.32 (+1.52%)
GE   82.36 (-1.52%)
DIS   94.71 (+2.33%)
AMC   6.00 (-1.15%)
PYPL   74.29 (+0.09%)
PFE   51.89 (+0.21%)
NFLX   327.58 (+5.58%)
S&P 500   3,976.40 (+0.33%)
DOW   33,840.90 (+0.18%)
QQQ   284.71 (+0.30%)
AAPL   144.39 (+1.22%)
MSFT   246.91 (-0.20%)
META   116.58 (+1.08%)
GOOGL   93.83 (+0.13%)
AMZN   89.62 (-0.81%)
TSLA   180.60 (+4.13%)
NVDA   174.79 (+1.81%)
NIO   12.98 (-3.21%)
BABA   92.89 (-1.36%)
AMD   70.39 (-0.11%)
T   19.33 (+1.10%)
MU   55.49 (+0.53%)
CGC   3.03 (-1.94%)
F   13.32 (+1.52%)
GE   82.36 (-1.52%)
DIS   94.71 (+2.33%)
AMC   6.00 (-1.15%)
PYPL   74.29 (+0.09%)
PFE   51.89 (+0.21%)
NFLX   327.58 (+5.58%)
NASDAQ:ADMA

ADMA Biologics - ADMA Stock Forecast, Price & News

$3.59
-0.05 (-1.37%)
(As of 12/9/2022 11:34 AM ET)
Add
Compare
Today's Range
$3.54
$3.65
50-Day Range
$2.43
$3.64
52-Week Range
$1.17
$3.72
Volume
116,652 shs
Average Volume
4.07 million shs
Market Capitalization
$706.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ADMA Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.7% Upside
$5.00 Price Target
Short Interest
Healthy
11.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of ADMA Biologics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.30) to ($0.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

419th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

69th out of 171 stocks

ADMA stock logo

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Stock News Headlines

ADMA Biologics hits 52-week high after strong Q3 beat
A Preview Of ADMA Biologics's Earnings
Top Penny Stocks for October 2022
ADMA Biologics, Inc. (ADMA)
Why ADMA Biologics Stock Triumphed on Thursday
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMA
Employees
527
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+39.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-71,650,000.00
Pretax Margin
-53.90%

Debt

Sales & Book Value

Annual Sales
$80.94 million
Book Value
$0.72 per share

Miscellaneous

Free Float
185,167,000
Market Cap
$706.44 million
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Adam S. GrossmanMr. Adam S. Grossman (Age 45)
    Co-Founder, Pres, CEO & Director
    Comp: $1.39M
  • Dr. Jerrold B. Grossman D.P.S. (Age 74)
    Ph.D., Co-Founder & Vice Chairman
    Comp: $70.9k
  • Mr. Brian Lenz CPAMr. Brian Lenz CPA (Age 50)
    CPA, Exec. VP, CFO & GM of ADMA BioCenters
    Comp: $1.02M
  • Ms. Kaitlin Kestenberg
    VP of Compliance, Project Management & Clinical Operations
  • Mr. Michael Goldstein
    Sr. Director & Gen. Counsel
  • Mr. Michael Least
    VP of Sales & Commercial Operations
  • Mr. Drew Pantello
    VP of Marketing & Corp. Devel.
  • Mr. Neal C. Fitzpatrick
    VP of Sales
  • Dr. Gene A. Wetzstein BCOP
    Pharm.D., Exec. Director & Head of Scientific Engagement
  • Ms. Cyndi Tolman
    Sr. VP of Plasma Services













ADMA Stock - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price forecast for 2023?

2 brokers have issued 1-year price objectives for ADMA Biologics' shares. Their ADMA share price forecasts range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 37.4% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2022?

ADMA Biologics' stock was trading at $1.41 at the beginning of 2022. Since then, ADMA stock has increased by 158.2% and is now trading at $3.64.
View the best growth stocks for 2022 here
.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a decline in short interest in November. As of November 15th, there was short interest totaling 21,740,000 shares, a decline of 15.9% from the October 31st total of 25,860,000 shares. Based on an average trading volume of 3,010,000 shares, the short-interest ratio is currently 7.2 days.
View ADMA Biologics' Short Interest
.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADMA earnings forecast
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $20.68 million for the quarter, compared to analyst estimates of $18.58 million. ADMA Biologics had a negative net margin of 53.89% and a negative trailing twelve-month return on equity of 52.73%. During the same period in the prior year, the firm posted ($0.19) EPS.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2024 earnings guidance on Friday, December, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250.00M-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.61%), Perceptive Advisors LLC (5.57%), State Street Corp (4.80%), Vanguard Group Inc. (4.73%), Nuveen Asset Management LLC (4.43%) and Boothbay Fund Management LLC (4.14%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends
.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $3.64.

How much money does ADMA Biologics make?

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $716.27 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does ADMA Biologics have?

The company employs 527 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 12/9/2022 by MarketBeat.com Staff